Medical Drugs News
-
BIO Announces NSF Track featuring 10 emerging biotech companies
The Biotechnology Industry Organization (BIO) today announced an agreement with the National Science Foundation (NSF) to bring SBIR-funded early-stage biotech companies to present at the 12th Annual BIO Investor Forum. The companies, funded by NSF and focused on drug discovery, diagnostics and other platform technologies, will participate in a dedicated track of company presentations. ...
-
AUC Launchs First University Spinoff Company in Egypt
The American University in Cairo (AUC) announced today, in a press conference held on Tahrir Square campus, the launch of Egypt’s first University spinoff company. The company, D-Kimia, develops novel and affordable diagnostic solutions to detect a broad range of diseases, initially focusing on the identification of the hepatitis C virus (HCV) that affects over 170 million people worldwide. ...
By D-Kimia, LLC
-
Pittcon 2014 Now Accepting Booth Space Reservations
The Pittcon Exposition Committee is now accepting booth space reservations for Pittcon 2014, which will be held March 3-6, 2014, at McCormick Place, North America’s premier convention facility, located in Chicago, Illinois. The discounted rate of $2,300 for a standard 10′ x 10′ space is available to all exhibitors until July 15, 2013. The cost per booth after July 15, is ...
-
TTIP and dancing elephants
On July 8 of this year, in Washington, D.C., the United States and the European Union launched negotiations on a proposed free trade agreement called the Transatlantic Trade and Investment Partnership, or TTIP. While the two parties have negotiated free trade agreements with other countries, they have not, until now, attempted one of this magnitude with one another.1 In its Technical Barriers to ...
-
Vybion`s Huntington Drug Neutralizes Critical Disease Driver
Vybion will present data on how its drug, INT41, alters a critical event in the development of Huntington's disease at the 7th Neurodegenerative Conditions Research & Development Conference in Boston on September 9-10, 2013. INT41 is an Intrabody drug delivered by Gene Therapy that blocks gene dysregulation in Huntington's Disease by neutralizing a toxic fragment of the Huntingtin mutant ...
By Vybion
-
New carbon footprint tool launched to calculate the carbon footprint of pharmaceutical products
ABPI (Association of the British Pharmaceutical Industry) collaborates with the Carbon Trust to help pharmaceutical companies quickly estimate the carbon footprint of tablet medicines distributed in blister packs ABPI (Association of the British Pharmaceutical Industry) collaborates with the Carbon Trust to help pharmaceutical companies quickly estimate the carbon footprint of tablet medicines ...
By Carbon Trust
-
Agilent Technologies enhances dissolution workstation software for greater instrument control and improved monitoring of pharmaceutical ingredients
Agilent Technologies Inc. (NYSE: A) today introduced an enhanced version of its Dissolution Workstation Software, providing better data integration, method change control and instrument monitoring for controlling multiple dissolution systems. Dissolution is a technique used in the pharmaceutical industry to determine the rate at which pure active pharmaceutical ingredients dissolve. The software ...
-
Lauren Sciences LLC awarded second Michael J. Fox Foundation grant to further develop V-Smart Therapeutic for Parkinson`s disease
New York, N.Y., June 25, 2013 -- Lauren Sciences LLC, a privately-held biotechnology company continuing development of its novel V-Smart™ platform technology, announced today the award of a second grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF). The company recently completed the first stage of developing V-Smart™-based therapeutics for the treatment of ...
-
Lauren Sciences independently recognized as a Technology Innovator in Drug Delivery with its V-Smart Platform, and selected as a Featured Company, in new report by MCD Group
New York, N.Y., June 18, 2013 -- Lauren Sciences, a privately-held biotechnology company furthering development of its novel V-Smart™ nanovesicle platform technology, announced today that it was independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in a new report by MCD Group. The report, "Early Stage Drug ...
-
Regulatory Developments - New EU Cosmetics Regulation Will Enter into Force on July 11, 2013
Regulation (EC) No. 1223/2009 of the European Parliament and of the Council of November 30, 2009, on Cosmetic Products will come into force on July 11, 2013, and repeals the Cosmetics Directive Regulation (Directive 76/768/EEC) provisions concerning carcinogenic, mutagenic, or toxic for reproduction (CMR) substances that have applied since December 1, 2010. The European Commission (EC) states ...
-
Eco Waste Solutions Reports Continued Growth in Mining sector and New Orders with Pharmaceutical and Government Labs
June 13, 2013 BURLINGTON, Ontario – Eco Waste Solutions (EWS) is proud to report that in the past six months it has received a total of eight contract awards to manufacture new plants for customers from a diverse range of industries. Eco Waste Solutions technology is relied upon for safe, effective, and environmentally responsible point-of-need waste disposal at mining operations around ...
-
DSM to contribute to new 2020 global nutrition target
/www.w3.org/1999/xhtml">DSM to contribute to new 2020 global nutrition target Royal DSM, the global Life Sciences and Materials Sciences company, today announced that it plans to help provide effective nutrition interventions to 50 million beneficiaries (pregnant and lactating woman and children under two) per year by 2020. This commitment is part of DSM's endorsement of the Global Nutrition ...
By DSM
-
Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer
/www.w3.org/1999/xhtml">Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer Novartis International AG / Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of ...
-
Europe’s environment now healthier – but new risks emerging
Europeans live longer and healthier lives than in the past, partly due to successful environmental policies that have reduced the exposure to harmful environmental contaminants in air, water and food, according to a new report. However, these contaminants are still a problem, and several new health risks are emerging, for example, from new chemicals, new products and changing lifestyle patterns. ...
-
Noble Awards $25,000 in Research Services to Synam Vaccine
Noble Awards $25,000 in Research Services to SynAm Vaccine Contributes Drug Development Services through InvestMaryland Business Competition Noble Life Sciences, Inc. (Gaithersburg, MD) awarded $25,000 of its drug development contract research services to SynAm Vaccine (Rockville, MD) as part of the InvestMaryland Challenge business competition. Organized by the state of Maryland, the ...
-
Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues
/www.w3.org/1999/xhtml">Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues Novartis International AG / Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no ...
-
Royal DSM, World Vision announce partnership to nourish millions of the world´s most vulnerable children
/www.w3.org/1999/xhtml">Royal DSM, World Vision announce partnership to nourish millions of the world's most vulnerable children Working together to achieve lasting progress in global health and development by improving the nutritional status of mothers and children Flagship programme in Tanzania to fortify maize flour with essential micronutrients 22 May 2013 - Royal ...
By DSM
-
New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations
/www.w3.org/1999/xhtml">New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations Novartis International AG / New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations . Processed and transmitted by Thomson ...
-
Agilent Technologies introduces verified dissolution components for pharmaceutical market
Agilent Technologies Inc. (NYSE: A) today introduced a new series of verified dissolution components, including molded vessels as well as paddle and basket shafts. Designed to ensure compliance with mechanical qualification guidelines, these components will be available June 1 and offer verification that they conform to exact specifications. Dissolution is a technique used in the pharmaceutical ...
-
NIH statement on Asthma Awareness Month
For Asthma Awareness Month 2013, the National Institutes of Health stands with the international community to renew our dedication to improving the quality of life for the estimated 300 million people living with asthma worldwide. To most effectively manage asthma, we need to address the disproportionate impact of the disease on minorities and families at or below the poverty line. NIH is ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you